Bach: Part B change could stem price hikes, hurt oncologists

In a Memorial Sloan Kettering Cancer Center.

The report said the proposed reimbursement change could dissuade manufacturers from raising prices because the payment rate for infused drugs is based on an average sales price (ASP) calculation that lags by two quarters. Physicians paying a new, higher price for a drug would still be reimbursed at a rate tied to its old price, and in some cases could lose money when prescribing the drug. ...